Appeals court upholds canceled patent for blockbuster MS drug

Oct 15, 2018

On Friday, an appeals court upheld an earlier ruling that canceled patents for a blockbuster multiple sclerosis drug owned by Teva Pharmaceuticals. 

The original ruling canceled patents for the drug, Copaxone, in January 2017 after a Delaware judge decided that they describe obvious concepts. The ruling is a victory for several manufacturers looking to get into the market for a generics version, including Mylan and Novartis AG. 

As of last year, Copaxone was generating about $4 billion in annual sales for Teva. 

Read the full Reuters report.

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments